Reviewing OncoSec Medical Incorporated (ONCS)’s and uniQure N.V. (NASDAQ:QURE)’s results

As Biotechnology companies, OncoSec Medical Incorporated (NASDAQ:ONCS) and uniQure N.V. (NASDAQ:QURE) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OncoSec Medical Incorporated N/A 0.00 40.81M -1.01 0.00
uniQure N.V. 12.26M 112.34 88.89M -2.69 0.00

Table 1 demonstrates OncoSec Medical Incorporated and uniQure N.V.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has OncoSec Medical Incorporated and uniQure N.V.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
OncoSec Medical Incorporated 0.00% -179.5% -144.8%
uniQure N.V. -725.04% -58.5% -35.9%

Risk & Volatility

OncoSec Medical Incorporated is 92.00% more volatile than Standard & Poor’s 500 due to its 1.92 beta. uniQure N.V. has a 0.77 beta and it is 23.00% less volatile than Standard & Poor’s 500.

Liquidity

OncoSec Medical Incorporated’s Current Ratio is 4.9 while its Quick Ratio is 4.9. On the competitive side is, uniQure N.V. which has a 7.6 Current Ratio and a 7.6 Quick Ratio. uniQure N.V. is better positioned to pay off short and long-term obligations compared to OncoSec Medical Incorporated.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for OncoSec Medical Incorporated and uniQure N.V.

Sell Ratings Hold Ratings Buy Ratings Rating Score
OncoSec Medical Incorporated 0 1 0 2.00
uniQure N.V. 0 0 2 3.00

uniQure N.V. on the other hand boasts of a $60 consensus price target and a 62.25% potential upside.

Institutional and Insider Ownership

OncoSec Medical Incorporated and uniQure N.V. has shares held by institutional investors as follows: 12.4% and 78%. OncoSec Medical Incorporated’s share held by insiders are 2.4%. Insiders Comparatively, held 0.1% of uniQure N.V. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OncoSec Medical Incorporated -0.59% 1.77% -43.9% -40.05% -48.82% -46.14%
uniQure N.V. -0.96% 3.94% -26.49% -14% 70.39% 48.03%

For the past year OncoSec Medical Incorporated has -46.14% weaker performance while uniQure N.V. has 48.03% stronger performance.

Summary

uniQure N.V. beats OncoSec Medical Incorporated on 7 of the 10 factors.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte; and a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the combination of OncoSec's ImmuoPulse IL-12 with MerckÂ’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase II clinical trial referred to as PISCES. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.